Lantheus Biosciences Ltd. — Biomedical Watch V2

Traitements6programmes

Essais3liés

Publications3liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
[18F]PI-2620The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.	Alzheimer, Parkinson	Phase 3	À vérifier	United States	À vérifier
Neuraceq (florbetaben 18F)This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom: 1. lumbar puncture was not feasible for medical conditions 2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians 3. lumbar puncture (LP) was refused by the patient	Alzheimer	Phase 4	À vérifier	France	À vérifier
PETThis phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom: 1. lumbar puncture was not feasible for medical conditions 2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians 3. lumbar puncture (LP) was refused by the patient	Alzheimer	Phase 4	À vérifier	France	À vérifier
[18F]PI-2620The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.	Parkinson	Phase 2	À vérifier	United States	À vérifier
Neuraceq (florbetaben 18F)This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom: 1. lumbar puncture was not feasible for medical conditions 2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians 3. lumbar puncture (LP) was refused by the patient	Alzheimer	Phase 4	À vérifier	France	À vérifier
[18F]PI-2620The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.	Alzheimer	Phase 3	À vérifier	United States	À vérifier

Essais cliniques

3

Molécule	Indication / population	Phase	NCT	Titre	Statut
[18F]PI-2620	Alzheimer	Phase 3	NCT05641688	[18F]PI-2620 Phase 3 Histopathological Study	RECRUITING
Neuraceq (florbetaben 18F)	Alzheimer	Phase 4	NCT02681172	Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD	COMPLETED
[18F]PI-2620	Parkinson	Phase 2	NCT07020026	Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease	RECRUITING

Publications

3

Molécule	Indication / population	Titre	Journal	Date
[18F]PI-2620		Developing a novel reference region for [F]PI-2620-PET imaging to facilitate the assessment of 4-repeat tauopathies.	European journal of nuclear medicine and molecular imaging
[18F]PI-2620		Association of functional brain alterations with β-amyloid, tau, and cognitive decline in Alzheimer's disease.	Alzheimer's research & therapy
[18F]PI-2620		Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.	European journal of nuclear medicine and molecular imaging